Discovery research: The scientific challenge of finding new antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 1941-1944

  Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antibacterial discovery; Antibiotic discovery; Antimicrobial discovery; Genomics; High throughput screening

Indexed keywords

AMIKACIN; AN 3365; ANTIBIOTIC AGENT; AVIBACTAM; BETA LACTAM; CARBAPENEM; DNA TOPOISOMERASE; FOSFOMYCIN; GLYCYLCYCLINE DERIVATIVE; GSK 052; GSK 1322322; GSK 225105; KANAMYCIN; LIPOPEPTIDE; ME 1071; MK 7655; NALIDIXIC ACID; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; TP 434; UNCLASSIFIED DRUG;

ALGORITHM; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG CONFORMATION; DRUG INDUSTRY; DRUG POTENCY; DRUG RESEARCH; DRUG TARGETING; GENE LIBRARY; GENE MUTATION; GENOMICS; HUMAN; HYDROGEN BOND; IN VITRO STUDY; LIPOPHILICITY; MUTATIONAL ANALYSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CAPITAL EXPENDITURES; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; GENOMICS; HUMANS;

EID: 80051703609     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr262     Document Type: Article

References (27)

1. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6: 427-30.
2. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-4.
3. Payne DJ, Gwynn MN, Holmes DJ et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.
4. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24: 71-109.
5. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 Suppl 2: S120-6.
6. Bush K. Alarming b-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 2010; 13: 558-64.
7. Zhou Y, Yu H, Guo Q et al. Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high-level resistance to aminoglycosides. Eur J Clin Microbiol Infect Dis 2010; 29: 1349-53.
8. Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta 2009; 1794: 769-81.
9. Payne DJ, Miller WH, Berry V et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob Agents Chemother 2002; 46: 3118-24.
10. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-49.
11. Bax BD, Chan PF, Eggleston DS et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 2010; 466: 935-40.
12. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 2010; 23: 160-201.
13. Ishii Y, Eto M, Mano Y et al. In vitro potentiation of carbapenems with ME1071, a novel metallo-b-lactamase inhibitor, against metallob-lactamase- producing Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2010; 54: 3625-9.
14. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem Pharmacol 2006; 71: 910-8.
15. Clark RB, He M, Fyfe C et al. 8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents. J Med Chem 2011; 54: 1511-28.
16. Walker K. Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 1. IDrugs 2010; 13: 743-5.
17. Vaara M. Polymyxins and their novel derivatives. Curr Opin Microbiol 2010; 13: 574-81.
18. Baker SJ, Tomsho JW, Benkovic SJ. Boron-containing inhibitors of synthetases. Chem Soc Rev 2011; doi:10.1039/C0CS00131G.
19. Rios JL, Recio MC. Medicinal plants and antimicrobial activity. J Ethnopharmacol 2005; 100: 80-4.
20. Goodfellow M, Fiedler HP. A guide to successful bioprospecting: informed by actinobacterial systematics. Antonie Van Leeuwenhoek 2010; 98: 119-42.
21. Barke J, Seipke RF, Gruschow S et al. A mixed community of actinomycetes produce multiple antibiotics for the fungus farming ant Acromyrmex octospinosus. BMC Biol 2010; 8: 109.
22. Baltz RH. Molecular engineering approaches to peptide, polyketide and other antibiotics. Nat Biotechnol 2006; 24: 1533-40.
23. Martin JF, Liras P. Engineering of regulatory cascades and networks controlling antibiotic biosynthesis in Streptomyces. Curr Opin Microbiol 2010; 13: 263-73.
24. Laureti L, Song L, Huang S et al. Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens. Proc Natl Acad Sci USA 2011; 108: 6258-63.
25. Hughes B. A Wellcome experiment in seeding drug discovery. Nat Rev Drug Discov 2010; 9: 178-80.
26. Aggen JB, Armstrong ES, Goldblum AA et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 2010; 54: 4636-42.
27. Shlaes D. Can the NIH rescue antibiotics from the FDA? Available online at http://antibiotics-theperfectstorm.blogspot.com/2011/01/can-nih-rescue-antibiotics-from-fda.html (19 April 2011, date last accessed).